Elliott Associates wants to buy Endologix for $2.25 per share

By Lisa Kerner

Charlotte, N.C., Oct 14 - Endologix, Inc. investors led by Elliott Associates, LP sent a letter to the company's board of directors saying they are willing to acquire 100% of the outstanding shares of Endologix for $2.25 cash per share.

The acquisition would be completed using Elliott's own funds and would not be subject to any financing condition, according to the shareholder's Oct. 13 letter. The letter was included as part of a schedule 13D filing with the Securities and Exchange Commission.

According to Elliott, the per-share offer price is a 69% premium over the closing share price of Endologix on Friday.

Elliott Associates and Elliott International, LP collectively own 14.5% of Endologix.

Endologix is an Irvine, Calif., company that develops minimally invasive treatments for vascular diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.